Monoclonal Antibodies

A monoclonal antibody is an antibody produced from a single clone of cells — so every molecule is identical and binds to one specific target.

(Higher Tier only — monoclonal antibodies are assessed on the Higher Tier papers.)

To make sense of the name, break it into two ideas you already know:

• Antibody — a protein made by white blood cells (lymphocytes) that binds to a specific antigen. An antigen is a molecule, usually a protein, found on the surface of a cell or pathogen.
• Monoclonal — "mono" means one, a "clone" is a group of genetically identical cells. So a monoclonal antibody comes from one clone of identical cells, all making the same antibody.

Term	Meaning
Antigen	A molecule (usually a protein) the immune system recognises
Antibody	A protein that binds to one specific antigen
Clone	A group of genetically identical cells
Monoclonal	Made by a single clone — every antibody molecule is identical

A monoclonal antibody is specific to one binding site on one protein antigen, so it can target one specific chemical or one specific type of cell in the body.

This specificity is the whole point. Because each antibody locks onto only one antigen, monoclonal antibodies can be aimed at a single target — one hormone, one pathogen, or the cells of one tumour — while ignoring everything else.

To make a useful supply of identical antibodies, scientists need a cell that does two jobs at once — and no natural cell does both.

A lymphocyte is the white blood cell that actually makes a chosen antibody. If you inject a mouse with an antigen, its lymphocytes respond by producing antibodies against that antigen. So lymphocytes solve the first half of the problem: they make exactly the antibody you want.

The catch is that lymphocytes do not divide well outside the body. Isolated in the lab, they make antibody for a short time and then die. You cannot grow them into the large, long-lasting population needed to harvest antibody in bulk.

Cell type	Makes the antibody?	Divides indefinitely?
Lymphocyte	Yes	No
Tumour cell	No	Yes
Hybridoma	Yes	Yes

The solution is to combine the lymphocyte with a cell that can divide endlessly — a tumour cell. Tumour cells divide rapidly and without limit, but they do not make the antibody you need. Fuse the two and you get a single cell with both useful properties. That fused cell is called a hybridoma.

The production process turns one antibody-making lymphocyte into a factory that produces a single antibody in bulk. Follow the flow from the mouse to the purified antibody:

Each step has a job. Walk through the logic rather than memorising words:

1. Stimulate the mouse. The mouse is injected with the antigen so its lymphocytes are stimulated to make the specific antibody against it.
2. Take the lymphocytes. These are the only cells that make the exact antibody required — but on their own they will not keep dividing.
3. Fuse with a tumour cell. A lymphocyte is combined with a particular kind of tumour cell.
4. The hybridoma forms. The hybridoma cell both divides quickly and makes the antibody — it has inherited one useful property from each parent cell.
5. Clone the hybridoma. Single hybridoma cells are cloned to produce many identical cells that all make the same antibody.
6. Collect and purify. Because the cloned cells divide so fast, a large amount of the antibody can be collected and purified.

Exam phrasing: lymphocytes are stimulated to make the antibody, they are combined with a tumour cell to form a hybridoma, the hybridoma is cloned, and the antibody is collected and purified. Use those verbs in order.

Exam questions love to ask why a tumour cell is used. The answer comes straight from comparing what each parent cell can and cannot do.

Work through it as a justification:

• A lymphocyte makes the right antibody, but it cannot divide many times in culture, so on its own it could never produce enough antibody.
• A tumour cell divides rapidly and indefinitely, but it does not make the antibody you want.
• Fusing them creates a hybridoma that keeps both abilities: it divides quickly (from the tumour cell) and makes the specific antibody (from the lymphocyte).

A hybridoma = a lymphocyte (which makes the antibody) fused with a tumour cell (which divides indefinitely). The combination is what lets you make large quantities of one identical antibody.

Worked reasoning — answer in full. Suppose a 3-mark question asks: "Explain why a tumour cell is combined with a lymphocyte when making monoclonal antibodies."

A complete answer:

1. Lymphocytes make the required antibody but do not divide many times (1).
2. Tumour cells divide rapidly and indefinitely (1).
3. The hybridoma therefore divides quickly and makes the antibody, so large amounts of the antibody can be produced (1).

Notice that the marks come from contrasting the two cells, not from naming the hybridoma. State what each parent contributes and you capture every mark.

Because each monoclonal antibody binds to one specific antigen, it can be used wherever you need to find, measure, or target that one molecule or cell. The spec groups the uses into four areas.

Use	What the antibody binds to	How it is used
Diagnosis	A specific hormone or molecule	Pregnancy tests detect a hormone in urine
Measuring / detecting	Hormones, chemicals, or pathogens	Lab tests measure levels in blood, or detect a pathogen
Research	A specific molecule in a cell/tissue	The antibody carries a fluorescent dye to locate the molecule
Treatment	An antigen on diseased (e.g. cancer) cells	The antibody delivers a drug or radioactive substance to those cells

You are not expected to recall the details of any specific test or treatment. The skill the exam wants is to explain how one works when given the information — using the same idea every time: a monoclonal antibody binds to one specific antigen, and something useful is attached to it or triggered by the binding.

The common thread across every use: a monoclonal antibody binds to one specific antigen. Detection, measurement, location and targeted treatment are all just different things done once that binding happens.

A home pregnancy test is the classic application — and a favourite exam context. It detects the hormone hCG (human chorionic gonadotropin), which is present in the urine of a pregnant person.

(Extra context — the hormone's name, hCG, is not required by AQA 8461. The spec only needs you to explain how the test uses monoclonal antibodies, given that a pregnancy hormone is present.)

Walk through what happens, applying the binding rule at each step:

Reasoning through the two outcomes:

• Pregnant: the urine contains the hormone. The hormone binds the mobile antibodies, the complex is then caught by the fixed antibodies at the test line, the colour concentrates there, and a line appears — a positive result.
• Not pregnant: no hormone is present, so nothing is trapped at the test line and no line appears.

The exam point is the specificity: the test works only because the monoclonal antibodies bind to that one specific hormone and ignore everything else in the urine. If asked to explain a result, name the antibody–hormone binding as the cause of the colour change.

The most important treatment use is in cancer, where the antibody is turned into a guided delivery system.

Cancer cells carry antigens on their surface that healthy cells do not. A monoclonal antibody made against that antigen will bind to the cancer cells and nothing else. Attach a payload to the antibody and you deliver it straight to the tumour:

Payload attached to the antibody	Effect on the cancer cell
A radioactive substance	Radiation kills or damages the cell
A toxic drug	The drug kills the cell
A chemical that stops cells growing	Blocks the cell from growing and dividing

The antibody delivers the substance to the cancer cells without harming other cells in the body — the appeal is targeting the tumour while sparing healthy tissue.

This targeting was expected to make monoclonal antibodies a near-perfect treatment. In practice they have fallen short:

• Monoclonal antibodies create more side effects than expected.
• For that reason they are not yet as widely used as everyone hoped when they were first developed.

(Skills link — AQA WS 1.5: be ready to evaluate the advantages and disadvantages of monoclonal antibodies. Advantage: they target one specific cell or chemical. Disadvantage: they cause more side effects than hoped, limiting their use.)

A balanced exam answer states the advantage (specific targeting that spares healthy cells) and the disadvantage (more side effects than expected, so they are less widely used than hoped).

1. Saying the lymphocyte divides to make the antibody supply

The lymphocyte makes the antibody but does not divide well in culture. The dividing comes from the tumour cell. The hybridoma is what does both — credit is lost if you claim the lymphocyte alone produces the bulk supply.

2. Getting the two parent cells the wrong way round

Lymphocyte = makes the antibody. Tumour cell = divides quickly/indefinitely. Swapping these is the most common slip. The hybridoma inherits one ability from each.

3. Forgetting the antigen injection and the cloning steps

A full production answer starts with stimulating mouse lymphocytes with an antigen and ends with cloning the hybridoma and collecting and purifying the antibody. Jumping straight to "make a hybridoma" misses marks for the steps before and after.

4. Saying monoclonal antibodies bind to several targets

Each monoclonal antibody is specific to one binding site on one antigen. That single-target specificity is the reason the tests and treatments work — describe it, do not generalise it.

5. Treating monoclonal antibodies as a finished success story

The spec is explicit that they create more side effects than expected and are not yet as widely used as hoped. An evaluation question expects this limitation, not just the benefits.

6. Forgetting this topic is Higher Tier and Biology only

Monoclonal antibodies appear only on the Higher Tier Biology papers. They are not on the Foundation papers and not in Combined Science Trilogy, so target your revision to the right paper.